Reported covered position: Chief of Staff, Rep. Rosa DeLauro (D-CT); Legislative Director, Rep. Sherrod Brown (D-OH); Legislative Assistant, Rep. Tom Foglietta (D-PA)
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
S. 1126 - Concentrating on High-Value Alzheimer's Needs to Get to an End (CHANGE) Act of 2019; HR 2283 - CHANGE Act of 2019
S. 1126 - Concentrating on High-Value Alzheimer's Needs to Get to an End (CHANGE) Act of 2019; HR 2283 - CHANGE Act of 2019
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
GLOBAL DOWN SYNDROME FOUNDATION via FAEGRE BAKER DANIELS CONSULTING
2019 · fourth_quarter · 4A
Fiscal Year 2019 Labor HHS appropriations for Down Syndrome research
Support for Down Syndrome research funding
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Source: Senate LDA
| KEMPE FOUNDATION |
| 11 |
| 2015–2017 |
| PEAR THERAPEUTICS | 9 | 2018–2019 |
| THERMO FISHER SCIENTIFIC | 9 | 2018–2019 |
| MYRIAD GENETICS INC | 8 | 2018–2019 |
| ALLIANCE FOR SAFE ONLINE PHARMACIES (ASOP) | 5 | 2017 |
| ALLERGY & ASTHMA NETWORK | 4 | 2014–2015 |
| OREXIGEN THERAPEUTICS, INC. | 4 | 2014 |
S. 1126 - Concentrating on High-Value Alzheimer's Needs to Get to an End (CHANGE) Act of 2019; HR 2283 - CHANGE Act of 2019
Runaway and Homeless Youth and Trafficking Prevention Act of 2020
Client: GLOBAL DOWN SYNDROME FOUNDATION · Firm: FAEGRE BAKER DANIELS CONSULTING
Support for Down Syndrome research funding; H.R. 5191 - MIND Act.
Concentrating on High-value Alzheimer’s Needs to Get to an End (CHANGE) Act of 2019
Client: USAGAINST ALZHEIMER'S · Firm: FAEGRE BAKER DANIELS CONSULTING
S. 1126 - Concentrating on High-Value Alzheimer's Needs to Get to an End (CHANGE) Act of 2019; HR 2283 - CHANGE Act of 2019
Concentrating on High-value Alzheimer’s Needs to Get to an End (CHANGE) Act of 2019
Client: USAGAINST ALZHEIMER'S · Firm: FAEGRE BAKER DANIELS CONSULTING
S. 1126 - Concentrating on High-Value Alzheimer's Needs to Get to an End (CHANGE) Act of 2019; HR 2283 - CHANGE Act of 2019
Concentrating on High-value Alzheimer’s Needs to Get to an End (CHANGE) Act of 2019
Client: USAGAINST ALZHEIMER'S · Firm: FAEGRE BAKER DANIELS CONSULTING
S. 1126 - Concentrating on High-Value Alzheimer's Needs to Get to an End (CHANGE) Act of 2019; HR 2283 - CHANGE Act of 2019
Protecting Access to Medicare Act of 2014
Client: MYRIAD GENETICS, INC. · Firm: FAEGRE BAKER DANIELS CONSULTING
PL 113-93 (H.R. 4302) - Protecting Access to Medicare Act of 2014; Implementation of changes to Medicare payment for clinical laboratory tests.
Protecting Access to Medicare Act of 2014
Client: MYRIAD GENETICS, INC. · Firm: FAEGRE BAKER DANIELS CONSULTING
PL 113-93 (H.R. 4302) - Protecting Access to Medicare Act of 2014; Implementation of changes to Medicare payment for clinical laboratory tests.
Protecting Access to Medicare Act of 2014
Client: MYRIAD GENETICS, INC. · Firm: FAEGRE BAKER DANIELS CONSULTING
PL 113-93 (H.R. 4302) - Protecting Access to Medicare Act of 2014; Implementation of changes to Medicare payment for clinical laboratory tests.
Protecting Access to Medicare Act of 2014
Client: MYRIAD GENETICS, INC. · Firm: FAEGRE BAKER DANIELS CONSULTING
PL 113-93 (H.R. 4302) - Protecting Access to Medicare Act of 2014; Implementation of changes to Medicare payment for clinical laboratory tests.
Access to Marketplace Insurance Act
Client: IMMUNE DEFICIENCY FOUNDATION · Firm: FAEGRE BAKER DANIELS CONSULTING
Medicare coverage and payment for immune globulin (IG) treatments; Part B reimbursement issues; S. 1738 (Medicare Home Infusion Therapy Access Act); H.R. 3976 (Access to Marketplace Insurance Act)
Access to Marketplace Insurance Act
Client: IMMUNE DEFICIENCY FOUNDATION · Firm: FAEGRE BAKER DANIELS CONSULTING
Medicare coverage and payment for immune globulin (IG) treatments; Part B reimbursement issues; S. 1738 (Medicare Home Infusion Therapy Access Act); H.R. 3976 (Access to Marketplace Insurance Act)
Concentrating on High-Value Alzheimer's Needs to Get to an End (CHANGE) Act of 2018
Client: USAGAINST ALZHEIMER'S · Firm: FAEGRE BAKER DANIELS CONSULTING
S. 2387, H.R. 4957: Concentrating on High-Value Alzheimer's Needs to Get to an End (CHANGE) Act
Concentrating on High-Value Alzheimer's Needs to Get to an End (CHANGE) Act of 2018
Client: USAGAINST ALZHEIMER'S · Firm: FAEGRE BAKER DANIELS CONSULTING
S. 2387, H.R. 4957: Concentrating on High-Value Alzheimer's Needs to Get to an End (CHANGE) Act
To amend title 38, United States Code, to direct the Secretary of Veterans Affairs to establish Alzheimer's Disease research, education, and clinical centers.
Client: GLOBAL DOWN SYNDROME FOUNDATION · Firm: FAEGRE BAKER DANIELS CONSULTING
Support for Down syndrome research funding; H.R. 5191 MIND Act
To amend title 38, United States Code, to direct the Secretary of Veterans Affairs to establish Alzheimer's Disease research, education, and clinical centers.
Client: GLOBAL DOWN SYNDROME FOUNDATION · Firm: FAEGRE BAKER DANIELS CONSULTING
Support for Down syndrome research funding; H.R. 5191 MIND Act
Removing Barriers to Allergy Diagnostic Testing Act of 2018
Client: THERMO FISHER SCIENTIFIC · Firm: FAEGRE BAKER DANIELS CONSULTING
Asthma policies and diagnostic allergy test coverage; H.R. 5541 - Removing Barriers to Allergy Diagnostic Testing Act of 2018
Removing Barriers to Allergy Diagnostic Testing Act of 2018
Client: THERMO FISHER SCIENTIFIC · Firm: FAEGRE BAKER DANIELS CONSULTING
Asthma policies and diagnostic allergy test coverage; H.R. 5541 - Removing Barriers to Allergy Diagnostic Testing Act of 2018
Medicare Home Infusion Therapy Access Act of 2017
Client: IMMUNE DEFICIENCY FOUNDATION · Firm: FAEGRE BAKER DANIELS CONSULTING
Medicare coverage and payment for immune globulin (IG) treatments; Part B reimbursement issues; S. 1738 (Medicare Home Infusion Therapy Access Act); evaluation of IVIG Demonstration
Medicare Home Infusion Therapy Access Act of 2017
Client: IMMUNE DEFICIENCY FOUNDATION · Firm: FAEGRE BAKER DANIELS CONSULTING
Medicare coverage and payment for immune globulin (IG) treatments; Part B reimbursement issues; S. 1738 (Medicare Home Infusion Therapy Access Act); H.R. 3976 (Access to Marketplace Insurance Act)
Medicare Home Infusion Therapy Access Act of 2017
Client: IMMUNE DEFICIENCY FOUNDATION · Firm: FAEGRE BAKER DANIELS CONSULTING
Medicare coverage and payment for immune globulin (IG) treatments; Part B reimbursement issues; S. 1738 (Medicare Home Infusion Therapy Access Act); evaluation of IVIG Demonstration
Medicare Home Infusion Therapy Access Act of 2017
Client: IMMUNE DEFICIENCY FOUNDATION · Firm: FAEGRE BAKER DANIELS CONSULTING
Medicare coverage and payment for immune globulin (IG) treatments; Part B reimbursement issues; S. 1738 (Medicare Home Infusion Therapy Access Act); H.R. 3976 (Access to Marketplace Insurance Act)
Concentrating on High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2018
Client: USAGAINST ALZHEIMER'S · Firm: FAEGRE BAKER DANIELS CONSULTING
S. 2387, H.R. 4957: Concentrating on High-Value Alzheimer's Needs to Get to an End (CHANGE) Act
Concentrating on High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2018
Client: USAGAINST ALZHEIMER'S · Firm: FAEGRE BAKER DANIELS CONSULTING
S. 2387, H.R. 4957: Concentrating on High-Value Alzheimer's Needs to Get to an End (CHANGE) Act
Protecting Access to Medicare Act of 2014
Client: MYRIAD GENETICS, INC. · Firm: FAEGRE BAKER DANIELS CONSULTING
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests.
Protecting Access to Medicare Act of 2014
Client: MYRIAD GENETICS, INC. · Firm: FAEGRE BAKER DANIELS CONSULTING
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests.
Protecting Access to Medicare Act of 2014
Client: MYRIAD GENETIC LABORATORIES, INC. · Firm: FAEGRE BAKER DANIELS CONSULTING
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests.
Protecting Access to Medicare Act of 2014
Client: MYRIAD GENETIC LABORATORIES, INC. · Firm: FAEGRE BAKER DANIELS CONSULTING
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests.
Protecting Access to Medicare Act of 2014
Client: MYRIAD GENETICS, INC. · Firm: FAEGRE BAKER DANIELS CONSULTING
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests.
Medicare Home Infusion Therapy Access Act of 2017
Client: IMMUNE DEFICIENCY FOUNDATION · Firm: FAEGRE BAKER DANIELS CONSULTING
Medicare coverage and payment for immune globulin (IG) treatments; Part B reimbursement issues; S. 1738 (Medicare Home Infusion Therapy Access Act)
Protecting Access to Medicare Act of 2014
Client: MYRIAD GENETIC LABORATORIES, INC. · Firm: FAEGRE BAKER DANIELS CONSULTING
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests.
Protecting Access to Medicare Act of 2014
Client: MYRIAD GENETIC LABORATORIES, INC. · Firm: FAEGRE BAKER DANIELS CONSULTING
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests.
Protecting Access to Medicare Act of 2014
Client: MYRIAD GENETIC LABORATORIES, INC. · Firm: FAEGRE BAKER DANIELS CONSULTING
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests.
Protecting Access to Medicare Act of 2014
Client: MYRIAD GENETIC LABORATORIES, INC. · Firm: FAEGRE BAKER DANIELS CONSULTING
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests.
Protecting Access to Medicare Act of 2014
Client: MYRIAD GENETIC LABORATORIES, INC. · Firm: FAEGRE BAKER DANIELS CONSULTING
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests.
Protecting Access to Medicare Act of 2014
Client: MYRIAD GENETIC LABORATORIES, INC. · Firm: FAEGRE BAKER DANIELS CONSULTING
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests.
Protecting Access to Medicare Act of 2014
Client: MYRIAD GENETIC LABORATORIES, INC. · Firm: FAEGRE BAKER DANIELS CONSULTING
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests.
Protecting Access to Medicare Act of 2014
Client: MYRIAD GENETIC LABORATORIES, INC. · Firm: FAEGRE BAKER DANIELS CONSULTING
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests.
Protecting Access to Medicare Act of 2014
Client: MYRIAD GENETIC LABORATORIES, INC. · Firm: FAEGRE BAKER DANIELS CONSULTING
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests. FDA draft guidance to regulate laboratory developed tests and companion diagnostics Legislation to further regulate clinical labs under CLIA and FDA (legislation not yet introduced; discussion draft only - no HR #)
Protecting Access to Medicare Act of 2014
Client: MYRIAD GENETIC LABORATORIES, INC. · Firm: FAEGRE BAKER DANIELS CONSULTING
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests.
Protecting Access to Medicare Act of 2014
Client: MYRIAD GENETIC LABORATORIES, INC. · Firm: FAEGRE BAKER DANIELS CONSULTING
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests. FDA draft guidance to regulate laboratory developed tests and companion diagnostics Legislation to further regulate clinical labs under CLIA and FDA (legislation not yet introduced; discussion draft only - no HR #)
2019 · fourth_quarter · 4T
Fiscal Year 2019 labor HHS appropriations legislation; issues related to sepsis treatment and antibiotic stewardship.
Drug shortages
Asthma policies and diagnostic allergy test coverage; Removing Barriers to Allergy Diagnostics Testing Act of 2019
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
PEAR THERAPEUTICS via FAEGRE BAKER DANIELS CONSULTING
2019 · fourth_quarter · 4T
Increase awareness of clinical use of FDA cleared prescription digital therapeutics.
Medicare coverage of FDA cleared prescription digital therapeutics.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MYOTONIC DYSTROPHY FOUNDATION via FAEGRE BAKER DANIELS CONSULTING
2019 · fourth_quarter · 4T
Fiscal Year 2019 Defense appropriations legislation; Peer Review Medical Research Program and Congressionally Directed Medical Research Program
Increasing funding for Myotonic Dystrophy research; Fiscal Year 2019 Labor and HHS appropriations.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
MYRIAD GENETICS, INC. via FAEGRE BAKER DANIELS CONSULTING
2019 · fourth_quarter · 4T
PL 113-93 (H.R. 4302) - Protecting Access to Medicare Act of 2014; Implementation of changes to Medicare payment for clinical laboratory tests.
Draft legislation to regulate clinical labs under CLIA and FDA.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GLOBAL DOWN SYNDROME FOUNDATION via FAEGRE BAKER DANIELS CONSULTING
2019 · fourth_quarter · Q4
Fiscal Year 2019 Labor HHS appropriations for Down Syndrome research
Support for Down Syndrome research funding
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
USAGAINST ALZHEIMER'S via FAEGRE BAKER DANIELS CONSULTING
2019 · fourth_quarter · Q4
S. 1126 - Concentrating on High-Value Alzheimer's Needs to Get to an End (CHANGE) Act of 2019; HR 2283 - CHANGE Act of 2019
Fiscal Year 2020 funding for Alzheimer's disease research and policies to enhance NIH Alzheimer's research.
Filing targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
NOVAVAX via FAEGRE BAKER DANIELS CONSULTING
2019 · fourth_quarter · Q4
Vaccine policy issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
USAGAINST ALZHEIMER'S via FAEGRE BAKER DANIELS CONSULTING
2019 · third_quarter · Q3
S. 1126 - Concentrating on High-Value Alzheimer's Needs to Get to an End (CHANGE) Act of 2019; HR 2283 - CHANGE Act of 2019
Fiscal Year 2020 funding for Alzheimer's disease research and policies to enhance NIH Alzheimer's research.
Filing targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
THERMO FISHER SCIENTIFIC via FAEGRE BAKER DANIELS CONSULTING
2019 · third_quarter · Q3
Drug shortages
Fiscal Year 2019 labor HHS appropriations legislation; issues related to sepsis treatment and antibiotic stewardship.
Asthma policies and diagnostic allergy test coverage; Removing Barriers to Allergy Diagnostics Testing Act of 2019
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
PEAR THERAPEUTICS via FAEGRE BAKER DANIELS CONSULTING
2019 · third_quarter · Q3
Increase awareness of clinical use of FDA cleared prescription digital therapeutics.
Medicare coverage of FDA cleared prescription digital therapeutics.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MYRIAD GENETICS, INC. via FAEGRE BAKER DANIELS CONSULTING
2019 · third_quarter · Q3
PL 113-93 (H.R. 4302) - Protecting Access to Medicare Act of 2014; Implementation of changes to Medicare payment for clinical laboratory tests.
Draft legislation to regulate clinical labs under CLIA and FDA.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MYOTONIC DYSTROPHY FOUNDATION via FAEGRE BAKER DANIELS CONSULTING
2019 · third_quarter · Q3
Increasing funding for Myotonic Dystrophy research; Fiscal Year 2019 Labor and HHS appropriations.
Fiscal Year 2019 Defense appropriations legislation; Peer Review Medical Research Program and Congressionally Directed Medical Research Program
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
GLOBAL DOWN SYNDROME FOUNDATION via FAEGRE BAKER DANIELS CONSULTING
2019 · third_quarter · Q3
Fiscal Year 2019 Labor HHS appropriations for Down Syndrome research.
Support for Down Syndrome research funding.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVAVAX via FAEGRE BAKER DANIELS CONSULTING
2019 · third_quarter · Q3
Vaccine policy issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
USAGAINST ALZHEIMER'S via FAEGRE BAKER DANIELS CONSULTING
2019 · second_quarter · Q2
S. 1126 - Concentrating on High-Value Alzheimer's Needs to Get to an End (CHANGE) Act of 2019; HR 2283 - CHANGE Act of 2019
Fiscal Year 2020 funding for Alzheimer's disease research and policies to enhance NIH Alzheimer's research.
Filing targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
THERMO FISHER SCIENTIFIC via FAEGRE BAKER DANIELS CONSULTING
2019 · second_quarter · Q2
Drug shortages
Asthma policies and diagnostic allergy test coverage; Removing Barriers to Allergy Diagnostics Testing Act of 2019
Fiscal Year 2019 labor HHS appropriations legislation; issues related to sepsis treatment and antibiotic stewardship.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
PEAR THERAPEUTICS via FAEGRE BAKER DANIELS CONSULTING
2019 · second_quarter · Q2
Medicare coverage of FDA cleared prescription digital therapeutics.
Increase awareness of clinical use of FDA cleared prescription digital therapeutics.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MYRIAD GENETICS, INC. via FAEGRE BAKER DANIELS CONSULTING
2019 · second_quarter · Q2
Draft legislation to regulate clinical labs under CLIA and FDA.
PL 113-93 (H.R. 4302) - Protecting Access to Medicare Act of 2014; Implementation of changes to Medicare payment for clinical laboratory tests.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MYOTONIC DYSTROPHY FOUNDATION via FAEGRE BAKER DANIELS CONSULTING
2019 · second_quarter · Q2
Increasing funding for Myotonic Dystrophy research; Fiscal Year 2019 Labor and HHS appropriations.
Fiscal Year 2019 Defense appropriations legislation; Peer Review Medical Research Program and Congressionally Directed Medical Research Program
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
GLOBAL DOWN SYNDROME FOUNDATION via FAEGRE BAKER DANIELS CONSULTING
2019 · second_quarter · Q2
Fiscal Year 2019 Labor HHS appropriations for Down Syndrome research.
Support for Down Syndrome research funding.
Filing targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
NOVAVAX via FAEGRE BAKER DANIELS CONSULTING
2019 · second_quarter · Q2
Vaccine policy issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THERMO FISHER SCIENTIFIC via FAEGRE BAKER DANIELS CONSULTING
2019 · first_quarter · Q1
Fiscal Year 2019 labor HHS appropriations legislation; issues related to sepsis treatment and antibiotic stewardship.
Drug shortages
Asthma policies and diagnostic allergy test coverage; Removing Barriers to Allergy Diagnostics Testing Act of 2019
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
USAGAINST ALZHEIMER'S via FAEGRE BAKER DANIELS CONSULTING
2019 · first_quarter · Q1
General issues regarding Alzheimer's Disease
Work to revise and reintroduce the Concentrating on High-Value Alzheimer's Needs to Get to and End (CHANGE) Act.
Fiscal Year 2020 funding for Alzheimer's disease research and policies to enhance NIH Alzheimer's research.
Filing targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
IMMUNE DEFICIENCY FOUNDATION via FAEGRE BAKER DANIELS CONSULTING
2019 · first_quarter · Q1
Patient access to medications; general overview of primary immunodeficiency (PI) community.
Medicare coverage and payment for immune globulin (IG) treatments; Part B reimbursement issues; implementation of home infusion services payment; coding and coverage of forms of primary immunodeficiency (PI) Disease.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
PEAR THERAPEUTICS via FAEGRE BAKER DANIELS CONSULTING
2019 · first_quarter · Q1
Medicare coverage of FDA cleared prescription digital therapeutics.
Increase awareness of clinical use of FDA cleared prescription digital therapeutics.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MYRIAD GENETICS, INC. via FAEGRE BAKER DANIELS CONSULTING
2019 · first_quarter · Q1
PL 113-93 (H.R. 4302) - Protecting Access to Medicare Act of 2014; Implementation of changes to Medicare payment for clinical laboratory tests.
Draft legislation to regulate clinical labs under CLIA and FDA.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GLOBAL DOWN SYNDROME FOUNDATION via FAEGRE BAKER DANIELS CONSULTING
2019 · first_quarter · Q1
Support for Down Syndrome research funding; H.R. 5191 - MIND Act.
Fiscal Year 2019 Labor HHS appropriations for Down Syndrome research.
Filing targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
MYOTONIC DYSTROPHY FOUNDATION via FAEGRE BAKER DANIELS CONSULTING
2019 · first_quarter · Q1
Increasing funding for Myotonic Dystrophy research; Fiscal Year 2019 Labor and HHS appropriations.
Fiscal Year 2019 Defense appropriations legislation; Peer Review Medical Research Program and Congressionally Directed Medical Research Program
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
NOVAVAX via FAEGRE BAKER DANIELS CONSULTING
2019 · first_quarter · Q1
Vaccine policy issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THERMO FISHER SCIENTIFIC via FAEGRE BAKER DANIELS CONSULTING
2018 · fourth_quarter · Q4
Drug shortage prevention and abuse-deterrent pseudophedrine.
Fiscal year 2019 VA and labor HHS appropriations legislation; issues related to sepsis treatment and antibiotic stewardship
Asthma policies and diagnostic allergy test coverage; H.R. 5541 - Removing Barriers to Allergy Diagnostic Testing Act of 2018
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
PEAR THERAPEUTICS via FAEGRE BAKER DANIELS CONSULTING
2018 · fourth_quarter · Q4
Increase awareness of clinical use of FDA cleared prescription digital therapeutics
Medicare coverage of FDA cleared prescription digital therapeutics
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MYRIAD GENETICS, INC. via FAEGRE BAKER DANIELS CONSULTING
2018 · fourth_quarter · Q4
Draft legislation to regulate clinical labs under CLIA and FDA.
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MYOTONIC DYSTROPHY FOUNDATION via FAEGRE BAKER DANIELS CONSULTING
2018 · fourth_quarter · Q4
Increasing funding for Myotonic Dystrophy research; Fiscal year 2019 labor and HHS appropriations
Fiscal year 2019 defense appropriations legislation; Peer Review Medical Research Program and Congressional Directed Medical Research Program
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
GLOBAL DOWN SYNDROME FOUNDATION via FAEGRE BAKER DANIELS CONSULTING
2018 · fourth_quarter · Q4
Support for Down syndrome research funding; H.R. 5191 MIND Act
Fiscal year 2019 labor HHS appropriations for Down syndrome research
Filing targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
MYRIAD GENETICS, INC. via FAEGRE BAKER DANIELS CONSULTING
2018 · third_quarter · 3A
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests.
Draft legislation to regulate clinical labs under CLIA and FDA.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVAVAX via FAEGRE BAKER DANIELS CONSULTING
2018 · fourth_quarter · Q4
Vaccine policy issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
USAGAINST ALZHEIMER'S via FAEGRE BAKER DANIELS CONSULTING
2018 · fourth_quarter · Q4
General issues regarding Alzheimer's Disease
Fiscal year 2019 funding for Alzheimer's disease research
S. 2387, H.R. 4957: Concentrating on High-Value Alzheimer's Needs to Get to an End (CHANGE) Act
Filing targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
IMMUNE DEFICIENCY FOUNDATION via FAEGRE BAKER DANIELS CONSULTING
2018 · fourth_quarter · Q4
Patient access to medications; access to insurance coverage; patient protections in AHCA and BCRA; health care reform
Medicare coverage and payment for immune globulin (IG) treatments; Part B reimbursement issues; S. 1738 (Medicare Home Infusion Therapy Access Act); evaluation of IVIG Demonstration
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
THERMO FISHER SCIENTIFIC via FAEGRE BAKER DANIELS CONSULTING
2018 · third_quarter · Q3
Fiscal year 2019 VA and labor HHS appropriations legislation; issues related to sepsis treatment and antibiotic stewardship
Asthma policies and diagnostic allergy test coverage; H.R. 5541 - Removing Barriers to Allergy Diagnostic Testing Act of 2018
Drug shortage prevention and abuse-deterrent pseudophedrine.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
MYOTONIC DYSTROPHY FOUNDATION via FAEGRE BAKER DANIELS CONSULTING
2018 · third_quarter · Q3
Increasing funding for Myotonic Dystrophy research; Fiscal year 2019 labor and HHS appropriations
Fiscal year 2019 defense appropriations legislation; Peer Review Medical Research Program and Congressional Directed Medical Research Program
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
NOVAVAX via FAEGRE BAKER DANIELS CONSULTING
2018 · third_quarter · Q3
Vaccine policy issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MYRIAD GENETICS, INC. via FAEGRE BAKER DANIELS CONSULTING
2018 · third_quarter · Q3
Draft legislation to regulate clinical labs under CLIA and FDA.
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GLOBAL DOWN SYNDROME FOUNDATION via FAEGRE BAKER DANIELS CONSULTING
2018 · third_quarter · Q3
Fiscal year 2019 labor HHS appropriations for Down syndrome research
Support for Down syndrome research funding; H.R. 5191 MIND Act
Filing targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
PEAR THERAPEUTICS via FAEGRE BAKER DANIELS CONSULTING
2018 · third_quarter · Q3
Medicare coverage of FDA cleared prescription digital therapeutics
Increase awareness of clinical use of FDA cleared prescription digital therapeutics
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
IMMUNE DEFICIENCY FOUNDATION via FAEGRE BAKER DANIELS CONSULTING
2018 · third_quarter · Q3
Medicare coverage and payment for immune globulin (IG) treatments; Part B reimbursement issues; S. 1738 (Medicare Home Infusion Therapy Access Act); evaluation of IVIG Demonstration
Patient access to medications; access to insurance coverage; patient protections in AHCA and BCRA; health care reform
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
USAGAINST ALZHEIMER'S via FAEGRE BAKER DANIELS CONSULTING
2018 · third_quarter · Q3
S. 2387, H.R. 4957: Concentrating on High-Value Alzheimer's Needs to Get to an End (CHANGE) Act
Fiscal year 2019 funding for Alzheimer's disease research
General issues regarding Alzheimer's Disease
Filing targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
MYRIAD GENETICS, INC. via FAEGRE BAKER DANIELS CONSULTING
2018 · third_quarter · RR
Implementation of changes to Medicare payment for clinical laboratory tests. FDA draft guidance to regulate laboratory developed tests and companion diagnostics. Legislation to further regulate clinical labs under CLIA and FDA.
Implementation of changes to Medicare payment for clinical laboratory tests. FDA draft guidance to regulate laboratory developed tests and companion diagnostics. Legislation to further regulate clinical labs under CLIA and FDA.
MYRIAD GENETIC LABORATORIES, INC. via FAEGRE BAKER DANIELS CONSULTING
2018 · third_quarter · 3T
Implementation of changes to Medicare payment for clinical laboratory tests.
FDA draft guidance to regulate laboratory developed tests and companion diagnostics. Legislation to further regulate clinical labs under CLIA and FDA.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
USAGAINST ALZHEIMER'S via FAEGRE BAKER DANIELS CONSULTING
2018 · second_quarter · Q2
Concentrating on High-Value Alzheimer's Needs to Get to an End (CHANGE) Act
Fiscal year 2019 labor HHS appropriations
Alzheimer's Disease research
MYOTONIC DYSTROPHY FOUNDATION via FAEGRE BAKER DANIELS CONSULTING
2018 · second_quarter · Q2
Increasing funding for Myotonic Dystrophy research
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PEAR THERAPEUTICS via FAEGRE BAKER DANIELS CONSULTING
2018 · second_quarter · Q2
Medicare coverage of FDA cleared prescription digital therapeutics
Increase awareness of clinical use of FDA cleared prescription digital therapeutics
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MYRIAD GENETIC LABORATORIES, INC. via FAEGRE BAKER DANIELS CONSULTING
2018 · second_quarter · Q2
FDA draft guidance to regulate laboratory developed tests and companion diagnostics. Legislation to further regulate clinical labs under CLIA and FDA.
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THERMO FISHER SCIENTIFIC via FAEGRE BAKER DANIELS CONSULTING
2018 · second_quarter · Q2
Asthma policies and diagnostic allergy test coverage.
Drug shortage prevention and abuse-deterrent pseudophedrine.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GLOBAL DOWN SYNDROME FOUNDATION via FAEGRE BAKER DANIELS CONSULTING
2018 · second_quarter · Q2
Support for Down syndrome research funding
Filing targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
IMMUNE DEFICIENCY FOUNDATION via FAEGRE BAKER DANIELS CONSULTING
2018 · second_quarter · Q2
Medicare coverage and payment for immune globulin (IG) treatments; Part B reimbursement issues; S. 1738 (Medicare Home Infusion Therapy Access Act); H.R. 3976 (Access to Marketplace Insurance Act)
Patient access to medications; access to insurance coverage; patient protections in AHCA and BCRA; health care reform
Appropriations for NIH
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVAVAX via FAEGRE BAKER DANIELS CONSULTING
2018 · second_quarter · Q2
Vaccine policy issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GLOBAL DOWN SYNDROME FOUNDATION via FAEGRE BAKER DANIELS CONSULTING
2018 · first_quarter · 1A
Support for Down syndrome research funding
Filing targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
MYOTONIC DYSTROPHY FOUNDATION via FAEGRE BAKER DANIELS CONSULTING
2018 · first_quarter · 1A
Increasing funding for Myotonic Dystrophy research
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PEAR THERAPEUTICS via FAEGRE BAKER DANIELS CONSULTING
2018 · first_quarter · Q1
Medicare coverage of FDA cleared prescription digital therapeutics
Increase awareness of clinical use of FDA cleared prescription digital therapeutics
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
USAGAINST ALZHEIMER'S via FAEGRE BAKER DANIELS CONSULTING
2018 · first_quarter · Q1
Concentrating on High-Value Alzheimer's Needs to Get to an End (CHANGE) Act
Fiscal year 2018 and 2019 appropriations for Alzheimers Disease research
General issues regarding Alzheimer's Disease
IMMUNE DEFICIENCY FOUNDATION via FAEGRE BAKER DANIELS CONSULTING
2018 · first_quarter · Q1
Appropriations for NIH
Medicare coverage and payment for immune globulin (IG) treatments; Part B reimbursement issues; S. 1738 (Medicare Home Infusion Therapy Access Act); H.R. 3976 (Access to Marketplace Insurance Act)
Patient access to medications; access to insurance coverage; patient protections in AHCA and BCRA; health care reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THERMO FISHER SCIENTIFIC via FAEGRE BAKER DANIELS CONSULTING
2018 · first_quarter · Q1
Drug shortage prevention and abuse-deterrent pseudophedrine.
Asthma policies and diagnostic test reimbursement.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PEAR THERAPEUTICS via FAEGRE BAKER DANIELS CONSULTING
2018 · first_quarter · RR
Increase awareness of clinical use of FDA cleared prescription digital therapeutics and Medicare coverage
Increase awareness of clinical use of FDA cleared prescription digital therapeutics and Medicare coverage
MYRIAD GENETIC LABORATORIES, INC. via FAEGRE BAKER DANIELS CONSULTING
2018 · first_quarter · Q1
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests.
FDA draft guidance to regulate laboratory developed tests and companion diagnostics. Legislation to further regulate clinical labs under CLIA and FDA.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MYOTONIC DYSTROPHY FOUNDATION via FAEGRE BAKER DANIELS CONSULTING
2018 · first_quarter · Q1
Increasing funding for Myotonic Dystrophy research
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GLOBAL DOWN SYNDROME FOUNDATION via FAEGRE BAKER DANIELS CONSULTING
2018 · first_quarter · Q1
Support for Down syndrome research funding
Filing targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
NOVAVAX via FAEGRE BAKER DANIELS CONSULTING
2018 · first_quarter · Q1
Vaccine policy issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THERMO FISHER SCIENTIFIC via FAEGRE BAKER DANIELS CONSULTING
2018 · first_quarter · RR
Asthma policies and diagnostic test reimbursement. Drug shortage prevention and abuse-deterrent pseudophedrine.
Asthma policies and diagnostic test reimbursement. Drug shortage prevention and abuse-deterrent pseudophedrine.
USAGAINST ALZHEIMER'S via FAEGRE BAKER DANIELS CONSULTING
2017 · fourth_quarter · Q4
Alzheimer's Disease research
Policies to support beneficiaries with AD
General issues regarding Alzheimer's Disease
MYRIAD GENETIC LABORATORIES, INC. via FAEGRE BAKER DANIELS CONSULTING
2017 · fourth_quarter · Q4
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests.
FDA draft guidance to regulate laboratory developed tests and companion diagnostics. Legislation to further regulate clinical labs under CLIA and FDA.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MYOTONIC DYSTROPHY FOUNDATION via FAEGRE BAKER DANIELS CONSULTING
2017 · fourth_quarter · Q4
Increasing funding for Myotonic Dystrophy research
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GLOBAL DOWN SYNDROME FOUNDATION via FAEGRE BAKER DANIELS CONSULTING
2017 · fourth_quarter · Q4
Support for Down syndrome research funding
Filing targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
IMMUNE DEFICIENCY FOUNDATION via FAEGRE BAKER DANIELS CONSULTING
2017 · fourth_quarter · Q4
Appropriations for NIH
Patient access to medications; access to insurance coverage; patient protections in AHCA and BCRA; health care reform
Medicare coverage and payment for immune globulin (IG) treatments; Part B reimbursement issues; S. 1738 (Medicare Home Infusion Therapy Access Act)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVAVAX via FAEGRE BAKER DANIELS CONSULTING
2017 · fourth_quarter · Q4
Vaccine policy issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALLIANCE FOR SAFE ONLINE PHARMACIES (ASOP) via FAEGRE BAKER DANIELS CONSULTING
2017 · fourth_quarter · Q4
Opposition to prescription drug importation legislation; online drug safety
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MYOTONIC DYSTROPHY FOUNDATION via FAEGRE BAKER DANIELS CONSULTING
2017 · third_quarter · Q3
Increasing funding for Myotonic Dystrophy research
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MYOTONIC DYSTROPHY FOUNDATION via FAEGRE BAKER DANIELS CONSULTING
2017 · second_quarter · Q2
Increasing funding for Myotonic Dystrophy research
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MYOTONIC DYSTROPHY FOUNDATION via FAEGRE BAKER DANIELS CONSULTING
2017 · second_quarter · RR
Increasing funding for DM research
GLOBAL DOWN SYNDROME FOUNDATION via FAEGRE BAKER DANIELS CONSULTING
2017 · third_quarter · Q3
Support for Down syndrome research funding
Filing targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
MYRIAD GENETIC LABORATORIES, INC. via FAEGRE BAKER DANIELS CONSULTING
2017 · third_quarter · Q3
FDA draft guidance to regulate laboratory developed tests and companion diagnostics. Legislation to further regulate clinical labs under CLIA and FDA.
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALLIANCE FOR SAFE ONLINE PHARMACIES (ASOP) via FAEGRE BAKER DANIELS CONSULTING
2017 · third_quarter · Q3
Opposition to prescription drug importation legislation; online drug safety
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
IMMUNE DEFICIENCY FOUNDATION via FAEGRE BAKER DANIELS CONSULTING
2017 · third_quarter · Q3
Appropriations for NIH
Medicare coverage and payment for immune globulin (IG) treatments; Part B reimbursement issues; IVIG Access Act
Patient access to medications; access to insurance coverage; patient protections in AHCA and BCRA; health care reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
USAGAINST ALZHEIMER'S via FAEGRE BAKER DANIELS CONSULTING
2017 · third_quarter · Q3
Alzheimer's Disease research
General issues regarding Alzheimer's Disease
Appropriations for fiscal year 2018
KEMPE FOUNDATION via FAEGRE BAKER DANIELS CONSULTING
2017 · third_quarter · Q3
Enhancing federal funding for research on child abuse and neglect
Appropriations for research on child abuse and neglect
Increase federal support for research on child abuse and neglect
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
NOVAVAX via FAEGRE BAKER DANIELS CONSULTING
2017 · third_quarter · Q3
Vaccine policy issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
IMMUNE DEFICIENCY FOUNDATION via FAEGRE BAKER DANIELS CONSULTING
2017 · second_quarter · Q2
Medicare coverage and payment for immune globulin (IG) treatments; Part B reimbursement issues; IVIG Access Act
Appropriations for NIH
Patient access to medications; access to insurance coverage; patient protections in AHCA and BCRA
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
USAGAINST ALZHEIMER'S via FAEGRE BAKER DANIELS CONSULTING
2017 · second_quarter · Q2
Appropriations for Alzheimer's Disease
Alzheimer's Disease research
General issues regarding Alzheimer's Disease
KEMPE FOUNDATION via FAEGRE BAKER DANIELS CONSULTING
2017 · second_quarter · Q2
Enhancing federal funding for research on child abuse and neglect
Increase federal support for research on child abuse and neglect
Appropriations for research on child abuse and neglect
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
ALLIANCE FOR SAFE ONLINE PHARMACIES (ASOP) via FAEGRE BAKER DANIELS CONSULTING
2017 · second_quarter · Q2
Opposition to prescription drug importation legislation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVAVAX via FAEGRE BAKER DANIELS CONSULTING
2017 · second_quarter · Q2
Vaccine policy issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MYRIAD GENETIC LABORATORIES, INC. via FAEGRE BAKER DANIELS CONSULTING
2017 · second_quarter · Q2
FDA draft guidance to regulate laboratory developed tests and companion diagnostics. Legislation to further regulate clinical labs under CLIA and FDA.
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GLOBAL DOWN SYNDROME FOUNDATION via FAEGRE BAKER DANIELS CONSULTING
2017 · second_quarter · Q2
Support for Down syndrome research funding
Filing targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
NOVAVAX via FAEGRE BAKER DANIELS CONSULTING
2017 · first_quarter · Q1
Vaccine policy issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALLIANCE FOR SAFE ONLINE PHARMACIES (ASOP) via FAEGRE BAKER DANIELS CONSULTING
2017 · first_quarter · Q1
Opposition to prescription drug importation legislation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
IMMUNE DEFICIENCY FOUNDATION via FAEGRE BAKER DANIELS CONSULTING
2017 · first_quarter · Q1
Patient access to medications; access to insurance coverage; patient protections in AHCA
Appropriations for NIH
Medicare coverage and payment for immune globulin (IG) treatments
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
KEMPE FOUNDATION via FAEGRE BAKER DANIELS CONSULTING
2017 · first_quarter · Q1
Enhancing federal funding for research on child abuse and neglect
Increase federal support for research on child abuse and neglect
Appropriations for research on child abuse and neglect
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
ALLIANCE FOR SAFE ONLINE PHARMACIES (ASOP) via FAEGRE BAKER DANIELS CONSULTING
2017 · first_quarter · RA
Opposition to prescription drug importation legislation
USAGAINST ALZHEIMER'S via FAEGRE BAKER DANIELS CONSULTING
2017 · first_quarter · Q1
Alzheimer's Disease research
General issues regarding Alzheimer's Disease
Medicare coverage issues
MYRIAD GENETIC LABORATORIES, INC. via FAEGRE BAKER DANIELS CONSULTING
2017 · first_quarter · Q1
FDA draft guidance to regulate laboratory developed tests and companion diagnostics. Legislation to further regulate clinical labs under CLIA and FDA.
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
General issues regarding Alzheimer's Disease
Filing targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
Alzheimer's Disease research
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
Appropriations for Alzheimers research
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
Medicare coverage issues
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
Medicare coverage issues
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
Appropriations for Alzheimer's Disease
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE